Summary & Overview
CPT 90684: 21‑Valent Pneumococcal Vaccine, Intramuscular
CPT code 90684 denotes a 21‑valent pneumococcal vaccine administered intramuscularly to protect against multiple strains of Streptococcus pneumoniae. This immunization code is nationally relevant as pneumococcal disease remains a leading cause of vaccine‑preventable morbidity among older adults and certain high‑risk groups; broader valency vaccines aim to expand strain coverage and reduce invasive pneumococcal disease. Payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical purpose of the product, typical service settings, and what to expect in payer coverage considerations. The publication summarizes national benchmarks for utilization and reimbursement where available, highlights recent policy updates affecting vaccine coding and coverage, and outlines clinical context for use of higher‑valency pneumococcal vaccines. Where input data is absent, the report notes missing elements and focuses on available payer policies, billing considerations, and implications for ambulatory and pharmacy vaccination programs. The content is intended to inform billing staff, clinicians, and policy analysts about coding, common administrative contexts, and areas for payer policy attention related to CPT code 90684.
Billing Code Overview
CPT code 90684 represents an intramuscular pneumococcal vaccine product formulated to protect against 21 strains of Streptococcus pneumoniae. The code is used to report administration of this 21‑valent pneumococcal vaccine when given by a clinician.
Service Type: Vaccine administration / Immunization
Typical Site of Service: Outpatient clinics, physician offices, community vaccination sites, pharmacies, and other ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient presents to a primary care clinic for routine preventive care and vaccine review. The patient has chronic obstructive pulmonary disease (COPD) and diabetes mellitus type 2, placing them at increased risk for invasive pneumococcal disease. The clinician documents vaccination history, confirms indications for pneumococcal immunization, verifies no contraindications (e.g., severe allergic reaction to a prior dose or vaccine component), and administers the intramuscular 21‑valent pneumococcal vaccine 90684 in the deltoid. The visit includes vaccine counseling, informed consent, and observation for immediate adverse reaction for 15 minutes. Documentation captures vaccine product, lot number, expiration date, site and route of administration, VIS (vaccine information statement) given, and the patient’s consent. Billing is submitted under the vaccine administration line item and may include an evaluation and management (E/M) code for a separate identifiable service if appropriate, with applicable modifier(s) when required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Used when no modifier is applicable for the service. |
25 |